ArticleCancer medicine2019
Correlation between immune signature and high-density lipoprotein cholesterol level in stage II/III colorectal cancer.
Article in Cancer medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Blood lipid metabolic biomarkers are emerging as significant prognostic indicators for survival in cancer patients.BMC cancer · 2024Pooled it
- Role of PCSK9 in hallmarks of cancer: From mechanisms to interventions (Review).Oncology letters · 2026Review
- Association of Lipid and Inflammatory Profiles With Tumor Stage in Hepatocellular Carcinoma.Cancer medicine · 2026Article
- Atherogenic Lipid Indices in Colorectal Cancer: Metabolic Associations and Survival Outcomes.Diagnostics (Basel, Switzerland) · 2026Article
- Lipid profile-based prognostic nomograms for obstructive colorectal cancer: multi-cohort development and validation.Frontiers in medicine · 2026Article
- High-density lipoproteins. Part 2. Impact of disease states on functionality.American journal of preventive cardiology · 2025Article
- Dysregulated Cholesterol Metabolism and Its Impact on the Tumour Immune Response in Colorectal Cancer.Journal of cellular and molecular medicine · 2025Review
- Prognostic value of the non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) in patients with RAS-mutant metastatic colorectal cancer.Frontiers in nutrition · 2025Article
- Association between high-density lipoprotein cholesterol and 7-autoantibodies: a study on physical examination data from 2018 to 2023.Frontiers in endocrinology · 2025Article
- Article
- Lipid Profiles Impact on the Oncologic Outcome of Upper Tract Urothelial Carcinoma.World journal of oncology · 2024Article
- Cholesterol induction in CD8Cancer immunology, immunotherapy : CII · 2023Article
- Predictive and prognostic role of early apolipoprotein A-I alteration in recurrent or metastatic nasopharyngeal carcinoma patients treated with anti-PD-1 therapy.Cancer medicine · 2023Article
- High-Density Lipoprotein in Metabolic Disorders and Beyond: An Exciting New World Full of Challenges and Opportunities.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Association of plasma lipid metabolism profiles with overall survival for patients with gastric cancer undergoing gastrectomy based onNutrition & metabolism · 2023Article
- Predictive value of prognostic nutritional and systemic immune-inflammation indices for patients with microsatellite instability-high metastatic colorectal cancer receiving immunotherapy.Frontiers in nutrition · 2023Article
- Prognostic nomograms integrating preoperative serum lipid derivative and systemic inflammatory marker of patients with non-metastatic colorectal cancer undergoing curative resection.Frontiers in oncology · 2023Article
- Lipoproteins and cancer: The role of HDL-C, LDL-C, and cholesterol-lowering drugs.Biochemical pharmacology · 2022Review
- Blood cholesterol-to-lymphocyte ratio as a novel prognostic marker to predict postoperative overall survival in patients with colorectal cancer.World journal of surgical oncology · 2022Article
- Immune cell-lipoprotein imbalance as a marker for early diagnosis of non-small cell lung cancer metastasis.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An increasing amount of evidence suggests that high-density lipoprotein cholesterol (HDL-C) is related to a positive prognosis in various cancers. However, the correlation between HDL-C and the immune signature and the prognostic role of HDL-C in stage II/III colorectal cancer (CRC) has not been previously reported. A total of 667 CRC patients were enrolled and divided into two groups based on the lower limit of normal HDL-C values (0.78 mmol/L). We used Kaplan-Meier curves and the Cox regression model to analyze the prognostic role of HDL in both disease-free survival (DFS) and overall survival (OS). Fifty-five pairs of tumor tissues were selected according to the variation in HDL-C levels (high or low) and the matched characterizes (ages, T stage, and N stage). Using immunohistochemistry, tumor tissues were stained with antibodies against CD3, CD8, CD163, iNOS, Forkhead box P3 (FOXP3), and CD33. We calculated the density of positively-stained infiltrating cells in the tumor center (TC) and invasive margin (IM). We then used Spearman rank correlation to further investigate the relationship between HDL-C levels and the immune signatures. Our results revealed that compared to patients with high HDL-C levels, patients with low HDL-C levels had poor 3-year DFS (68.9% vs 83.1%, P = 0.032) and 5-year OS rates (66.6% vs 85.3%, P = 0.002). We also identified a positive correlation between HDL-C and CD3
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.